Micropos Medical (MPOS) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 reached 1,741 TSEK, up 277% year-over-year; full-year sales were 3,824 TSEK, up 133% year-over-year.

• Result after financial items for Q4 was -4,577 TSEK (improved from -5,724 TSEK); full-year result was -21,868 TSEK (improved from -23,540 TSEK).

• PACE-B study publication supports SBRT with five sessions, boosting Raypilot System's market prospects.

• New purchase orders and rental agreements for Raypilot System in Greece, Spain, and Switzerland.

• Focus on markets adopting SBRT, notably the UK, Switzerland, and Spain.

Financial highlights

• Gross margin for the year was 6% (30% in 2023).

• Solid equity ratio at 63% (54% in 2023); cash and cash equivalents at year-end were 7,968 TSEK (6,017 TSEK in 2023).

• Earnings per share for Q4 was -0.03 SEK (-0.04 SEK); full-year EPS was -0.14 SEK (-0.17 SEK).

• 12.7 million new shares issued during the year, raising 22,351 TSEK in equity.

Outlook and guidance

• SBRT is expected to become standard for prostate cancer in several countries, increasing demand for Raypilot System.

• Company will need new capital during H1 2025 due to slow ramp-up in patient treatments.

• Focus remains on markets with rapid SBRT adoption and on improving patient quality of life.